Literature DB >> 23727188

Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.

Dong Hoon Lee1, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Byung Ha Chung.   

Abstract

PURPOSE: We analyzed the pathological outcomes of candidates for active surveillance according to tumor lesion diameter on diffusion weighted magnetic resonance imaging.
MATERIALS AND METHODS: We retrospectively analyzed 188 candidates for active surveillance who had undergone diffusion weighted magnetic resonance imaging before radical prostatectomy between 2006 and 2012. We measured the diameter of the suspicious tumor lesion on diffusion weighted magnetic resonance imaging and stratified the cohort into 2 groups. Group 1 included patients with normal magnetic resonance imaging or a suspicious tumor lesion smaller than 1 cm and group 2 included patients with a suspicious tumor lesion larger than 1 cm. We compared pathological outcomes including insignificant prostate cancer in each group and analyzed whether different tumor diameters resulted in a change in insignificant prostate cancer rates.
RESULTS: Group 1 consisted of 115 (61.2%) patients and group 2 included 73 (38.8%) patients. In group 1 magnetic resonance imaging was normal in 72 patients. Mean ± SD diameter of suspicious tumor lesions was 12.0 ± 5.58 mm. Tumor volume was significantly different between the groups (0.73 ± 0.86 vs 1.09 ± 1.07 cm(3), p = 0.018), as was the rate of insignificant prostate cancer (48.7% vs 24.7%, p = 0.001). The rate of insignificant prostate cancer decreased as tumor diameter increased over 1 cm. On multivariate logistic regression analysis the diameter of suspicious tumor lesions was an important predictor of insignificant prostate cancer (OR 0.319, p = 0.014).
CONCLUSIONS: Our analysis demonstrates that the simple measurement of the diameter of suspicious tumor lesions on diffusion weighted magnetic resonance imaging could improve the prediction of insignificant prostate cancer in candidates for active surveillance.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADC; AS; DW-MRI; ECE; MRI; PRIAS; PSA; PSA density; PSAD; Prostate Cancer Research International: Active Surveillance; RP; SVI; active surveillance; apparent diffusion coefficient; diffusion magnetic resonance imaging; diffusion weighted magnetic resonance imaging; extracapsular extension; magnetic resonance imaging; prostate specific antigen; prostatic neoplasms; radical prostatectomy; seminal vesicle invasion; watchful waiting

Mesh:

Year:  2013        PMID: 23727188     DOI: 10.1016/j.juro.2013.03.127

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications.

Authors:  Lizhi Liu; Zhiqiang Tian; Zhenfeng Zhang; Baowei Fei
Journal:  Acad Radiol       Date:  2016-04-25       Impact factor: 3.173

2.  Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance.

Authors:  Robert R Flavell; Antonio C Westphalen; Carmin Liang; Christopher C Sotto; Susan M Noworolski; Daniel B Vigneron; Zhen J Wang; John Kurhanewicz
Journal:  Abdom Imaging       Date:  2014-10

Review 3.  The expanding landscape of diffusion-weighted MRI in prostate cancer.

Authors:  Andreas G Wibmer; Evis Sala; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Abdom Radiol (NY)       Date:  2016-05

4.  Clinical experience with active surveillance protocol using regular magnetic resonance imaging instead of regular repeat biopsy for monitoring: A study at a high-volume center in Korea.

Authors:  Hyun Kyu Ahn; Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  Prostate Int       Date:  2020-12-05

5.  Image-based monitoring of targeted biopsy-proven prostate cancer on active surveillance: 11-year experience.

Authors:  Sunao Shoji; Osamu Ukimura; Andre Luis de Castro Abreu; Arnaud Marien; Toru Matsugasumi; Duke Bahn; Inderbir S Gill
Journal:  World J Urol       Date:  2015-06-21       Impact factor: 3.661

6.  Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging.

Authors:  Ottavio de Cobelli; Daniela Terracciano; Elena Tagliabue; Sara Raimondi; Danilo Bottero; Antonio Cioffi; Barbara Jereczek-Fossa; Giuseppe Petralia; Giovanni Cordima; Gilberto Laurino Almeida; Giuseppe Lucarelli; Carlo Buonerba; Deliu Victor Matei; Giuseppe Renne; Giuseppe Di Lorenzo; Matteo Ferro
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

7.  Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.

Authors:  Hideyuki Akaza; Choung Soo Kim; Peter Carroll; In Young Choi; Byung Ha Chung; Matthew R Cooperberg; Yoshihiko Hirao; Shiro Hinotsu; Shigeo Horie; Ji Youl Lee; Mikio Namiki; Chi-Fai Ng; Mizuki Onozawa; Seiichiro Ozono; Satoru Ueno; Rainy Umbas; Dingwei Ye; Gang Zhu
Journal:  Prostate Int       Date:  2014-06-30

Review 8.  Current status of active surveillance in prostate cancer.

Authors:  Mun Su Chung; Seung Hwan Lee
Journal:  Investig Clin Urol       Date:  2016-01-11

9.  Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring.

Authors:  Dong Hoon Lee; Kyo Chul Koo; Seung Hwan Lee; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Byung Ha Chung
Journal:  Prostate Int       Date:  2014-06-30

Review 10.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.